CHMP recommends EU label update for Phesgo to allow administration outside of clinical settings May 6, 2025
Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications May 6, 2025
Plans for Ph 3 1L vepdegestrant combo trial with atirmociclib and Ph 3 2L combination trial with a CDK4/6 inhibitor shelved May 6, 2025
Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis May 6, 2025
CAPItello-280 Ph 3 trial of Truqap (capivasertib) + docetaxel and ADT in patients with metastatic CRPC to be discontinued May 6, 2025
FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer May 6, 2025
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of R/R Multiple Myeloma May 6, 2025
Cellipont Bioservices and Optieum Biotechnologies to Advance cGMP Manufacturing of OPTF01 for GBM May 6, 2025
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics May 6, 2025
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific ADC Program May 6, 2025
Ph 1 study targeting GPC3 with 225Ac-GPC3 (BAY 3547926) in patients with advanced HCC initiated May 6, 2025
Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer May 6, 2025
CR achieved after 1 month of the in vivo CD19 CAR-T treatment, with durable response sustained over three months in R/R DLBCL patients May 6, 2025
Higher Exposure of AFM24 Associated with Significantly Higher Response Rates and PFS in Refractory NSCLC Patients May 6, 2025
Tuspetinib-based Triplet regimen in 1L AML Patients in Ph 1/2 TUSCANY Trial Demonstrates Safety, Complete Remissions May 6, 2025
Supplemental BLA submission to FDA for Epcoritamab + Rituximab and Lenalidomide (R2) in Patients with R/R Follicular Lymphoma planned May 6, 2025
